Objective: This study aimed to assess the impact of common asthma medication regimens on asthma symptoms, exacerbations, lung function, and inflammation during pregnancy. Study Design: A total of 311 women with asthma were enrolled in a prospective pregnancy cohort. Asthma medication regimen was categorized into short-acting β agonist (SABA) alone, SABAtinhaled corticosteroid (ICS), SABAtICStlong-acting β agonist (LABA), and no asthma medications (reference). We evaluated asthma control at enrollment (< 15 weeks' gestation) and its change into trimesters 2 and 3, including per cent predicted forced expiratory volume in 1 second (%FEV1) and peak expiratory flow (%PEF), pulse oximetry, fractional exhaled nitric oxide (FeNO), asthma symptoms (asthma attacks/month, night symptoms/week), and severe exacerbations. Linear mixed models adjusted for site, age, race, annual income, gestational age, body mass index, and smoking, and propensity scores accounted for asthma control status at baseline. Results: Women taking SABAtICS and SABAtICStLABA had better first trimester % PEF (83.5% [18.104.22.168] and 84.6% [22.214.171.124], respectively) compared with women taking no asthma medications (72.7% [126.96.36.199]). Women taking SABAtICStLABA also experienced improvements in %FEV1 (t11.1%, p<0.01) in the third trimester and FeNO in the second (-12.3 parts per billion [ppb], p<0.01) and third (-11.0 ppb, p<0.01) trimesters as compared with the trajectory of women taking no medications.
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Pediatrics, Perinatology, and Child Health